Another acquisition involves the Roche health care group and medical device supplier Disetronic, the world’s second-largest maker of insulin pumps. Roche offered Disetronic shareholders two Roche non-voting equity securities and $489 for each Disetronic share. Based on mid-February exchange rates, the deal was worth some $1.2 billion.

Roche will be able to offer comprehensive diabetes management solutions, from blood glucose meters for self-monitoring to programmable insulin pumps that allow patients to administer insulin doses continuously according to their individual needs. However, Roche reported it would resell Disetronic Injection Systems to Disetronic’s founder and chairman Willy Michel for $306.6 million.